Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux

Exclusion Criteria

• •Concurrent laryngeal disease, if such disease or its treatment would interfere with evaluation of study results. For example, patients with mass lesions such as laryngeal cysts or laryngeal carcinoma will be excluded. Patients with acute laryngeal infections or acute laryngeal allergies will be excluded until these conditions have been resolved; but they may be considered for inclusion thereafter.
• •Any upper gastroenterological or esophageal surgery except simple over-sewing of a perforated ulcer.
• •Active substance abuse.
• •Tobacco use.
• •Known hypersensitivity or allergy to any protein pump inhibitor.
• •ALT (SGPT) or AST (SGOT) greater than 2 times the upper limit of normal.
• •Renal impairment (serum creatinine \> 2.0 mg/dl).
• •Any clinically significant, unstable medical condition.
• •Use of any proton pump inhibitor within 7 days prior to 24-hour pH impedance monitoring or baseline strobovideolaryngoscopy, or use of H2 receptor antagonist during the 48 hours prior to 24-hour pH impedance monitoring or baseline strobovideolaryngoscopy.
• •Use of an investigational drug or participation in an investigational study, within 30 days prior to starting study drug.
• •Previous participation in this study.
• •Pregnant women.
• •Women breast feeding infants.
• •Inability or refusal to follow directions.